AKBA - Akebia stock jumps as FDA clears renal anemia therapy
2024-03-28 05:42:57 ET
Akebia Therapeutics ( NASDAQ: AKBA ) shares surged over 25% premarket on Thursday after the U.S. Food and Drug Administration (FDA) approved its Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months....
Akebia stock jumps as FDA clears renal anemia therapy